SARS-CoV-2 mutations also lead to different pulmonary symptoms.These factors complicate predicting sivelestat's treatment effects from broad-syndrome trials [34].Despite these promising observations, robust evidence supporting the widespread use of neutrophil elastase inhibitors in COVID-19-induced ARDS remains insufficient. The gene discussed is ELANE; the disease is COVID-19.